Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

May 16, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

July 31, 2023

Conditions
Knee Osteoarthritis
Interventions
BIOLOGICAL

Mesenchymal progenitor cells

Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use

BIOLOGICAL

No mesenchymal progenitor cells

No mesenchymal progenitor cells for intra- articular use

Trial Locations (7)

100029

China-Japan Friendship Hospital, Beijing

200040

Huashan Hospital Affiliated to Fudan University, Shanghai

200080

Shanghai General Hospital, Shanghai

200127

Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai

200233

Shanghai Sixth People's Hospital, Shanghai

310009

The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou

Unknown

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

Shanghai 6th People's Hospital

OTHER

collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

collaborator

China-Japan Friendship Hospital

OTHER

collaborator

Huashan Hospital

OTHER

collaborator

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

lead

Shanghai AbelZeta Ltd.

INDUSTRY

NCT04208646 - Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis | Biotech Hunter | Biotech Hunter